Vaso, a medical technology company currently trading on the OTCQX market, announced its plan to merge with Achari Ventures Holdings I at a pro forma equity value of approximately $176 million.
If approved, Vaso stock and warrants are expected to list on the Nasdaq under the ticker symbols VASO and VASOW. Until then, Vaso’s common stock will continue to trade on the OTCQX market under the symbol VASO.
The target is a diversified medical technology company with several specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.
Ladenburg Thalmann is serving as financial and capital markets advisor to Vaso. Katten Muchin Rosenman is legal advisor to Achari and Ortoli Rosenstadt is legal advisor to Vaso.
The SPAC raised $100 million in an October 2021 IPO with initial plans to focus on cannabis companies. Since then, redemptions on extension votes have erased nearly 94% of the trust, which now stands at about $6.7 million. Read more.
